Beigene Email Format

Pharmaceutical Manufacturing
10,001+ employees
Cambridge, MA, USA

Beigene is a global oncology company discovering and developing innovative cancer treatments across hematology and solid tumors for patients worldwide.

Find contacts at Beigene

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@beigene.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
2010
Headquarters
Cambridge, MA, USA
Revenue
$2.5B-$5B
FUNDING Stage
Public
Key Executives
John V. Oyler (Co-Founder, Chairman & Chief Executive Officer), Aaron Rosenberg (Chief Financial Officer), Xiaobin Wu (President & Chief Operating Officer)

Tech Stack

Workday

Infrastructure

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Beigene?

Beigene uses the first.last format on beonemedicines.com, so Jane Smith would be jane.smith@beonemedicines.com.

What cancer types does Beigene focus on in its research and development pipeline?

Beigene focuses its R&D pipeline on hematology and solid tumors, targeting cancers with the highest unmet need including blood, lung, breast, gynecological, gastrointestinal, and rare cancers across more than 180 clinical trials globally.

How many countries does Beigene have regulatory approvals in for its internally developed medicines?

Beigene has received regulatory approval for its three internally developed medicines in more than 80 countries and regions across six continents, with clinical trials planned or enrolled in over 45 countries.

What is Beigene's BRUKINSA and which blood cancers is it approved to treat?

BRUKINSA (zanubrutinib) is a next-generation BTK inhibitor developed by Beigene and approved to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom's macroglobulinemia, and mantle cell lymphoma, among other indications.

Where can I find the right Beigene contact for outreach or verify a specific employee email address?

Clay can help you verify Beigene employee email addresses or build a targeted contact list by enriching records with the confirmed first.last@beonemedicines.com format used across the company's roughly 12,000 employees worldwide.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles